A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)
NCT05543174
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
7
Enrollment
INDUSTRY
Sponsor class
Conditions
Alagille Syndrome (ALGS)
Interventions
DRUG:
TAK-625
Sponsor
Takeda